National Cancer Institute and the Food and Drug Administration

Riepilogo

The National Cancer Institute (NCI) and the Food and Drug Administration (FDA), wherein the participation of the FDA is contingent on resolution of any apparent conflict of interest issues, seek a company that can collaboratively pursue the pre-clinical and clinical development of Soluble Tat Peptide Analogs for the Inhibition of HIV Transcription and Viral Replication. The National Cancer Institute, Laboratory of Molecular Virology (LMV) and the Food and Drug Administration, Center for Biologics, Laboratory of Immunochemistry, have established that particular Soluble Tat Peptide Analogs can inhibit the transcription and replication of the Human Immunodeficiency Virus in vitro. The selected sponsor will be selected as a CRADA partner for the co-development of this agent with the National Cancer Institute and the Food and Drug Administration for the co-development of this agent with the NCI and with the FDA, wherein the participation of the FDA is contingent on resolution of any apparent conflict of interest issues.